Page 125 - 《中国药房》2024年6期

[16] 孟文静，汪旭，贾勇圣，等. 阿瑞匹坦预防高致吐性化疗 [J]. J Clin Oncol，2001，19（6）：1759-1767.
所致恶心呕吐的效果和安全性评价[J]. 吉林大学学报 [24] 赵宁莉，李歆，秦叔逵，等. 注射用福沙匹坦双葡甲胺对
（医学版），2016，42（2）：331-335. 比阿瑞匹坦预防国人高致吐性化疗所致的恶心、呕吐的
MENG W J，WANG X，JIA Y S，et al. Efficacy and safety 随机、双盲双模拟、平行对照的多中心Ⅲ期临床试验报
evaluation on aprepitant in prevention of nausea and vo- 告[J]. 临床肿瘤学杂志，2020，25（8）：702-709.
miting induced by highly emetogenic chemotherapy[J]. J ZHAO N L，LI X，QIN S K，et al. A randomized，double-
Jilin Univ Med Ed，2016，42（2）：331-335. blind，double-simulation，parallel control and multicenter
[17] 芦婷婷，田欣 . 阿瑞匹坦对结肠癌 FOLFOX6 方案化疗 phase Ⅲ clinical trial comparing fosaprepitant injection
患者相关恶心呕吐的预防效果观察[J]. 山东医药，2018， with aprepitant tablet in the prevention of nausea and vomi-
58（32）：77-79. ting caused by highly emetogenic chemotherapy in Chinese
LU T T，TIAN X. Observation on the preventive effect of patients[J]. Chin Clin Oncol，2020，25（8）：702-709.
aprepitant on nausea and vomiting in patients with colon [25] 齐婧. 阿瑞匹坦对乳腺癌AC方案化疗后中重度呕吐患
cancer undergoing FOLFOX6 chemotherapy[J]. Shan‐ 者的二级预防[J]. 药学实践杂志，2017，35（2）：158-
dong Med J，2018，58（32）：77-79. 160，181.
[18] SCHWARTZBERG L，MOSIER M，GELLER R，et al. QI J. Aprepitant as secondary prevention in moderate-
APF530 for nausea and vomiting prevention following severe vomiting caused by AC chemotherapy for breast
cisplatin：phase 3 MAGIC trial analysis[J]. J Community cancer[J]. J Pharm Pract，2017，35（2）：158-160，181.
Support Oncol，2017，15（2）：82-88. [26] HERRINGTON J D，JASKIEWICZ A D，SONG J. Ran‐
[19] 王涛，黄迪泽，徐丹，等. 阿瑞匹坦在预防肺癌含铂化疗 domized，placebo-controlled，pilot study evaluating aprepi‐
方案所致化疗相关性恶心呕吐的疗效研究[J]. 中国医药 tant single dose plus palonosetron and dexamethasone for
科学，2018，8（15）：87-90. the prevention of acute and delayed chemotherapy-
WANG T，HUANG D Z，XU D，et al. Research of clinical induced nausea and vomiting[J]. Cancer，2008，112（9）：
effect of aprepitant in prevention of chemotherapy asso- 2080-2087.
ciated nausea and vomiting induced by platinum chemo‐ [27] KIM J E，JANG J S，KIM J W，et al. Erratum to：efficacy
therapy in lung cancer[J]. China Med Pharm，2018，8 and safety of aprepitant for the prevention of chemo-
（15）：87-90. therapy-induced nausea and vomiting during the first
[20] 田欣，宣莹，胡天玉，等. NK-1抑制剂预防头颈部恶性肿 cycle of moderately emetogenic chemotherapy in Korean
瘤PF方案化疗相关恶心、呕吐的疗效观察[J]. 医学研究 patients with a broad range of tumor types[J]. Support
杂志，2016，45（11）：49-53. Care Cancer，2017，25（5）：1741.
TIAN X，XUAN Y，HU T Y，et al. Clinical observation of [28] SCHMOLL H J，AAPRO M S，POLI-BIGELLI S，et al.
NK1 receptor antagonist aprepitant for the prevention of Comparison of an aprepitant regimen with a multiple-day
nausea and vomiting induced by PF chemotherapy regi‐ ondansetron regimen，both with dexamethasone，for anti‐
men with head and neck cancer[J]. J Med Res，2016，45 emetic efficacy in high-dose cisplatin treatment[J]. Ann
（11）：49-53. Oncol，2006，17（6）：1000-1006.
[21] SCHMITT T，GOLDSCHMIDT H，NEBEN K，et al. [29] RAPOPORT B L，JORDAN K，BOICE J A，et al. Aprepi‐
Aprepitant，granisetron，and dexamethasone for preven‐ tant for the prevention of chemotherapy-induced nausea
tion of chemotherapy-induced nausea and vomiting after and vomiting associated with a broad range of moderately
high-dose melphalan in autologous transplantation for emetogenic chemotherapies and tumor types：a rando-
multiple myeloma：results of a randomized，placebo- mized，double-blind study[J]. Support Care Cancer，2010，
controlled phase Ⅲ trial[J]. J Clin Oncol，2014，32（30）： 18（4）：423-431.
3413-3420. [30] POLI-BIGELLI S，RODRIGUES-PEREIRA J，CARIDES
[22] HU Z H，CHENG Y，ZHANG H Y，et al. Aprepitant triple A D，et al. Addition of the neurokinin 1 receptor antago‐
therapy for the prevention of chemotherapy-induced nau‐ nist aprepitant to standard antiemetic therapy improves
sea and vomiting following high-dose cisplatin in Chinese control of chemotherapy-induced nausea and vomiting.
patients：a randomized，double-blind，placebo-controlled Results from a randomized， double-blind， placebo-
phase Ⅲ trial[J]. Support Care Cancer，2014，22（4）： controlled trial in Latin America[J]. Cancer，2003，97
979-987. （12）：3090-3098.
[23] CAMPOS D，PEREIRA J R，REINHARDT R R，et al. [31] MARU A，GANGADHARAN V P，DESAI C J，et al. A
Prevention of cisplatin-induced emesis by the oral neuro- phase 3，randomized，double-blind study of single-dose fo‐
kinin-1 antagonist，MK-869，in combination with grani- saprepitant for prevention of cisplatin-induced nausea and
setron and dexamethasone or with dexamethasone alone vomiting：results of an Indian population subanalysis[J].

中国药房 2024年第35卷第6期 China Pharmacy 2024 Vol. 35 No. 6 · 755 ·